EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michalopoulos, A.
Right arrow Articles by Geroulanos, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michalopoulos, A.
Right arrow Articles by Geroulanos, S.

European Journal of Cardio-Thoracic Surgery, Vol 11, 728-731, Copyright © 1997 by European Association for Cardio-thoracic Surgery


ARTICLES

Systemic candidiasis in cardiac surgery patients

A Michalopoulos, J Kriaras and S Geroulanos
Cardiothoracic ICU, Onassis Cardiac Surgery Center, Athens, Greece.

OBJECTIVE: To examine the frequency, predisposing factors and consequences of systemic candidiasis in cardiac surgery patients. We also examined fluconazole efficacy in the treatment of disseminated fungal disease. METHODS: A total of 2615 adult patients of mean +/- S.D. age 60.8 +/- 8.7 years who underwent open heart surgery between July 1993 and April 1995, were enrolled in the initial protocol. Patients were divided in two groups according to length of stay in the intensive care unit (ICU). The cut-off was a length of stay of 9 days. RESULTS: In the group of patients with prolonged stay (n = 54), 11 patients (20.3%) developed systemic candidiasis, usually after the twentieth postoperative day. Predisposing factors were patient age, history of diabetes mellitus, presence of central venous catheters, prolonged mechanical ventilatory support, prolonged ICU stay, and administration of antibiotics and of total parenteral nutrition for a prolonged period. The patients who developed systemic candidiasis had a median ICU and hospital stay of 58 and 60 days respectively. The mortality rate was 27.2%. Patients receiving fluconazole, improved and eventually negative cultures were obtained. CONCLUSIONS: We concluded that a significant percentage of patients who remained in the cardiothoracic ICU for more than 9 days developed systemic candidiasis. Systemic candidiasis resulted in a significant prolongation of ICU and hospital length of stay, thus increasing extensively total hospitalization costs. Fluconazole seems to be an effective and well- tolerated agent in the treatment of severe life-threatening systemic candidiasis, and a very good alternative to amphotericin B, in cardiac surgery patients.


This article has been cited by other articles:


Home page
ChestHome page
A. S. Michalopoulos, S. Geroulanos, and S. D. Mentzelopoulos
Determinants of Candidemia and Candidemia-Related Death in Cardiothoracic ICU Patients
Chest, December 1, 2003; 124(6): 2244 - 2255.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.